Serotonin, hypertension and vascular disease

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Biochemistry

Background:

• Circulating serotonin (5-hydroxytryptamine) originates in the gut and is stored in platelets.
• Platelet aggregation releases serotonin, amplifying the process and potentially causing vasoconstriction.
• Endothelial cells uptake and metabolize serotonin, releasing endothelium-derived relaxing factor (EDRF).

Purpose of the Study:

• To investigate the mechanisms by which 5HT2-serotonergic antagonists influence platelet aggregation and vascular tone.
• To elucidate the role of serotonin in platelet-endothelial cell-vascular smooth muscle interactions.
• To determine how 5HT2 antagonists modulate serotonin-induced vascular effects.

Main Methods:

• Investigated the effects of 5-hydroxytryptamine (serotonin) on platelet aggregation and vascular smooth muscle.
• Examined the influence of 5HT2-serotonergic antagonists on these processes.
• Assessed the role of endothelial cells and endothelium-derived relaxing factor (EDRF) in mediating serotonin's effects.
• Utilized pertussis toxin to probe G-protein involvement in EDRF release.

Main Results:

• 5HT2-serotonergic antagonists inhibit serotonin-mediated amplification of platelet aggregation.
• Serotonin typically causes vascular smooth muscle contraction, an effect often blocked by 5HT2 antagonists.
• Endothelium-dependent relaxation is facilitated by 5HT2 antagonists, counteracting serotonin's direct vasoconstrictive effects.
• Serotonin's proliferative effect on vascular smooth muscle may also be inhibited by these antagonists.

Conclusions:

• 5HT2-serotonergic antagonists promote vasodilation by inhibiting platelet aggregation and direct vascular smooth muscle activation.
• These antagonists enhance endothelium-dependent relaxations, contributing to a vasodilatory effect.
• The findings suggest a significant role for 5HT2 receptors in regulating vascular tone and platelet function.